BACKGROUND: Computed tomographic pulmonary angiography (CTPA) may improve detection of life-threatening pulmonary embolism (PE), but this sensitive test may have a downside: overdiagnosis and overtreatment (finding clinically unimportant emboli and exposing patients to harms from unnecessary treatment). METHODS: To assess the impact of CTPA on national PE incidence, mortality, and treatment complications, we conducted a time trend analysis using the Nationwide Inpatient Sample and Multiple Cause-of-Death databases. We compared age-adjusted incidence, mortality, and treatment complications (in-hospital gastrointestinal tract or intracranial hemorrhage or secondary thrombocytopenia) of PE among US adults before (1993-1998) and after (1998-2006) CTPA was introduced. RESULTS: Pulmonary embolism incidence was unchanged before CTPA (P = .64) but increased substantially after CTPA (81% increase, from 62.1 to 112.3 per 100,000; P < .001). Pulmonary embolism mortality decreased during both periods: more so before CTPA (8% reduction, from 13.4 to 12.3 per 100,000; P < .001) than after (3% reduction, from 12.3 to 11.9 per 100,000; P = .02). Case fatality improved slightly before (8% decrease, from 13.2% to 12.1%; P = .02) and substantially after CTPA (36% decrease, from 12.1% to 7.8%; P < .001). Meanwhile, CTPA was associated with an increase in presumed complications of anticoagulation for PE: before CTPA, the complication rate was stable (P = .24), but after it increased by 71% (from 3.1 to 5.3 per 100,000; P < .001). CONCLUSIONS: The introduction of CTPA was associated with changes consistent with overdiagnosis: rising incidence, minimal change in mortality, and lower case fatality. Better technology allows us to diagnose more emboli, but to minimize harms of overdiagnosis we must learn which ones matter.
BACKGROUND: Computed tomographic pulmonary angiography (CTPA) may improve detection of life-threatening pulmonary embolism (PE), but this sensitive test may have a downside: overdiagnosis and overtreatment (finding clinically unimportant emboli and exposing patients to harms from unnecessary treatment). METHODS: To assess the impact of CTPA on national PE incidence, mortality, and treatment complications, we conducted a time trend analysis using the Nationwide Inpatient Sample and Multiple Cause-of-Death databases. We compared age-adjusted incidence, mortality, and treatment complications (in-hospital gastrointestinal tract or intracranial hemorrhage or secondary thrombocytopenia) of PE among US adults before (1993-1998) and after (1998-2006) CTPA was introduced. RESULTS:Pulmonary embolism incidence was unchanged before CTPA (P = .64) but increased substantially after CTPA (81% increase, from 62.1 to 112.3 per 100,000; P < .001). Pulmonary embolism mortality decreased during both periods: more so before CTPA (8% reduction, from 13.4 to 12.3 per 100,000; P < .001) than after (3% reduction, from 12.3 to 11.9 per 100,000; P = .02). Case fatality improved slightly before (8% decrease, from 13.2% to 12.1%; P = .02) and substantially after CTPA (36% decrease, from 12.1% to 7.8%; P < .001). Meanwhile, CTPA was associated with an increase in presumed complications of anticoagulation for PE: before CTPA, the complication rate was stable (P = .24), but after it increased by 71% (from 3.1 to 5.3 per 100,000; P < .001). CONCLUSIONS: The introduction of CTPA was associated with changes consistent with overdiagnosis: rising incidence, minimal change in mortality, and lower case fatality. Better technology allows us to diagnose more emboli, but to minimize harms of overdiagnosis we must learn which ones matter.
Authors: M Carrier; M Righini; P S Wells; A Perrier; D R Anderson; M A Rodger; S Pleasance; G Le Gal Journal: J Thromb Haemost Date: 2010-06-07 Impact factor: 5.824
Authors: William Nicholson; W Jay Nicholson; Paul Tolerico; Bradley Taylor; Samuel Solomon; Thomas Schryver; Kevin McCullum; Howard Goldberg; James Mills; Brian Schuler; Larry Shears; Lyle Siddoway; Nikhilesh Agarwal; Christopher Tuohy Journal: Arch Intern Med Date: 2010-08-09
Authors: Conrad Wittram; Margaret J Meehan; Elkan F Halpern; Jo-Anne O Shepard; Theresa C McLoud; James H Thrall Journal: J Thorac Imaging Date: 2004-07 Impact factor: 3.000
Authors: David J Schultz; Karen J Brasel; Lacey Washington; Lawrence R Goodman; Robert R Quickel; Randolph J Lipchik; Todd Clever; John Weigelt Journal: J Trauma Date: 2004-04
Authors: Carolin Pütter; Olga von Beckerath; Hanna Maria Sobik; Holger Reinecke; Jürgen Stausberg; Knut Kröger Journal: J Thromb Thrombolysis Date: 2015-11 Impact factor: 2.300
Authors: Jamal H Mahar; Ihab Haddadin; Divyajot Sadana; Abishek Gadre; Natalie Evans; Deborah Hornacek; Natalia Fendrikova Mahlay; Marcelo Gomes; Douglas Joseph; Maya Serhal; Michael Zhen-Yu Tong; Seth R Bauer; Michael Militello; Bernard Silver; Mehdi Shishehbor; John R Bartholomew; Gustavo A Heresi Journal: J Thromb Thrombolysis Date: 2018-08 Impact factor: 2.300
Authors: Sean B Smith; Jeffrey B Geske; Parul Kathuria; Michael Cuttica; Daniel R Schimmel; D Mark Courtney; Grant W Waterer; Richard G Wunderink Journal: Chest Date: 2016-02-18 Impact factor: 9.410
Authors: Michael D Repplinger; Rebecca L Bracken; Brian W Patterson; Manish N Shah; Michael S Pulia; John B Harringa; Mark L Schiebler; Scott K Nagle Journal: J Am Coll Radiol Date: 2018-04-30 Impact factor: 5.532
Authors: Wei Huang; Robert J Goldberg; Frederick A Anderson; Catarina I Kiefe; Frederick A Spencer Journal: Am J Med Date: 2014-05-06 Impact factor: 4.965